These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 19859900

  • 1. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study.
    Costa R, Carneiro A, Rocha A, Pirraco A, Falcão M, Vasques L, Soares R.
    J Cell Biochem; 2009 Dec 15; 108(6):1410-7. PubMed ID: 19859900
    [Abstract] [Full Text] [Related]

  • 2. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
    Barzelay A, Lowenstein A, George J, Barak A.
    Curr Eye Res; 2010 Sep 15; 35(9):835-41. PubMed ID: 20795866
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
    Carneiro A, Falcão M, Pirraco A, Milheiro-Oliveira P, Falcão-Reis F, Soares R.
    Exp Eye Res; 2009 Mar 15; 88(3):522-7. PubMed ID: 19135441
    [Abstract] [Full Text] [Related]

  • 4. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.
    Exp Eye Res; 2007 Oct 15; 85(4):425-30. PubMed ID: 17714704
    [Abstract] [Full Text] [Related]

  • 5. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
    Stewart EA, Samaranayake GJ, Browning AC, Hopkinson A, Amoaku WM.
    Exp Eye Res; 2011 Nov 15; 93(5):761-6. PubMed ID: 21970900
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.
    Retina; 2012 Mar 15; 32(3):434-57. PubMed ID: 22374154
    [Abstract] [Full Text] [Related]

  • 8. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
    Deissler H, Deissler H, Lang S, Lang GE.
    Br J Ophthalmol; 2008 Jun 15; 92(6):839-43. PubMed ID: 18511543
    [Abstract] [Full Text] [Related]

  • 9. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P.
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec 15; 245(12):1837-42. PubMed ID: 17347807
    [Abstract] [Full Text] [Related]

  • 10. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS, Aisenbrey S.
    Br J Ophthalmol; 2013 Jul 15; 97(7):917-23. PubMed ID: 23686000
    [Abstract] [Full Text] [Related]

  • 11. Comparing protein VEGF inhibitors: In vitro biological studies.
    Yu L, Liang XH, Ferrara N.
    Biochem Biophys Res Commun; 2011 May 06; 408(2):276-81. PubMed ID: 21501594
    [Abstract] [Full Text] [Related]

  • 12. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
    Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P, Tuebingen Bevacizumab Study Group.
    Br J Ophthalmol; 2006 Oct 06; 90(10):1316-21. PubMed ID: 16723358
    [Abstract] [Full Text] [Related]

  • 13. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.
    Machalińska A, Paczkowska E, Pabin T, Safranow K, Karczewicz D, Machaliński B.
    J Ocul Pharmacol Ther; 2011 Oct 06; 27(5):471-5. PubMed ID: 21830945
    [Abstract] [Full Text] [Related]

  • 14. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2012 Jul 06; 96(7):1023-8. PubMed ID: 22539748
    [Abstract] [Full Text] [Related]

  • 15. Multiple effects of bevacizumab in angiogenesis: implications for its use in age-related macular degeneration.
    Carneiro A, Falcão M, Azevedo I, Falcão Reis F, Soares R.
    Acta Ophthalmol; 2009 Aug 06; 87(5):517-23. PubMed ID: 18717653
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic anti-VEGF antibodies.
    Lien S, Lowman HB.
    Handb Exp Pharmacol; 2008 Aug 06; (181):131-50. PubMed ID: 18071944
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2011 Aug 06; 95(8):1151-6. PubMed ID: 21273213
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.
    Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU.
    Br J Ophthalmol; 2007 Jun 06; 91(6):827-31. PubMed ID: 17179166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.